The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?

Cancer Policy

NIH agrees to review hundreds of denied or shelved grant applications

House passes three-year extension of ACA subsidies with bipartisan support

Merck & Co. drug for treating NSCLC awarded FDA priority voucher

FDA-mandated report finds “insufficient data” to determine safety of PFAS in cosmetics

Journal retracts decades-old study that determined glyphosate, widely used herbicide, as safe

CMS awards $50 billion for rural health care after states compete for funding

Clinical Roundup

HRSA releases updated cervical cancer screening guidelines

Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

Inflammatory immune cells predict survival, relapse in MM, WashU-led study finds

Breast cancer drug boosts leukemia treatment, OHSU-led study finds

RNA splicing errors drive leukemia, UMiami-led study finds

Researchers decipher mechanism enabling breast cancer to metastasize to the brain

In The Clinic
Free

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

Regulatory News
Trials & Tribulations
Trials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account